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Abstract Background: Patients with metastatic colorectal cancer (mCRC) previously-treated
with oxaliplatin beneﬁt signiﬁcantly from the addition of aﬂibercept to FOLFIRI in relation
to overall survival, progression-free survival and response rate.
Patients and methods: The results for efﬁcacy and safety over the time course of the VEGF
Trap (aﬂibercept) with irinotecan in colorectal cancer after failure of oxaliplatin regimen
trial were analysed based on data from 1226 patients randomised to receive FOLFIRI plus
either aﬂibercept (n = 612) or placebo (n = 614). Hazard ratios (HR) by 6-month time
period were estimated using a piecewise Cox proportional hazard model. Severity of adverse
events (AEs) was graded using National Cancer Institute Common Terminology Criteria,
version 3.0.
Results: The estimated probabilities of survival were 38.5% versus 30.9% at 18 months,
28.0% versus 18.7% at 24 months and 22.3% versus 12.0% at 30 months, for the aﬂibercept-
and placebo-treated arms, respectively. The proportional improvement in the HR over time
was consistent with the survival probability results; survival at 24 months was improved by
50% and almost doubled at 30 months. The majority of worst-grade AEs occurred within
the ﬁrst four cycles of treatment and in a small percent of treatment cycles and were mostly
reversible. Common chemotherapy- and anti-vascular epithelial growth factor (VEGF)-
associated AEs occurred rarely and in a small proportion of cycles with the majority being
of single occurrence.
Conclusions: The addition of aﬂibercept to FOLFIRI showed a continued and persistent
improvement in overall survival over time in patients with mCRC. Although grade 3–4
AEs were more frequent in the aﬂibercept arm, they occurred in early treatment cycles
and decreased sharply following initial presentation.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Treatment of metastatic colorectal cancer (mCRC)
typically involves a ﬂuoropyrimidine-based chemother-
apy regimen, combining infusional ﬂuorouracil (5-FU)
and leucovorin with oxaliplatin (FOLFOX regimen) or
irinotecan (FOLFIRI regimen) [1–3]. The anti-
angiogenic agent bevacizumab has also been shown to
increase survival when added ﬁrst-line to irinotecan,
bolus 5-FU and leucovorin (IFL) [4]. Subsequent trials
have demonstrated that infusional chemotherapy regi-
mens, such as FOLFIRI and FOLFOX confer an
improvement over IFL [5] and consequently these infu-
sional chemotherapy backbones are now typically the
ones used in combination with targeted agents in the
ﬁrst-line treatment of mCRC [5]. Treatment choices
for patients with relapsed mCRC following progression
typically involve a cross-over to an alternative regimen,
which is predicated by the ﬁrst-line therapy received as
well as geographic preferences for certain chemotherapy
agents [6–8]. Randomised phase III studies have investi-
gated the eﬃcacy and safety of both anti-angiogenic and
anti-epidermal growth factor receptor (EGFR) biologics
in combination with FOLFOX or FOLFIRI for the
treatment of mCRC in the second-line setting in patients
both with and without a prior history of bevacizumab
therapy [9–14]. In particular, the Treatment through
Multiple Lines (ﬁrst and second line) trial showed that
vascular epithelial growth factor (VEGF) inhibition
with bevacizumab plus an alternate standard second-line
chemotherapy beyond disease progression has beneﬁt in
terms of median overall survival (OS) in patients with
mCRC who were previously treated with bevacizumab
and a standard chemotherapy backbone [10,11]. In the
E3200 study, it was shown that the addition of bev-
acizumab to FOLFOX improves survival duration for
patients with previously treated mCRC who had not
received ﬁrst-line treatment with oxaliplatin or bev-
acizumab [10]. VEGF Trap (aﬂibercept) with irinotecan
in colorectal cancer after failure of oxaliplatin regimen
(VELOUR) was the ﬁrst randomised, placebo-
controlled, phase III trial to show a statistically signiﬁ-
cant improvement in OS, progression-free survival
(PFS) and response rate (RR) for an antiangiogenic in
combination with FOLFIRI compared with FOLFIRI
alone in a prior oxaliplatin-treated population [9].
Aﬂibercept (VEGF Trap, AVE0005, or ziv-aﬂibercept
in the United States) is a novel fusion protein which
binds all isoforms of human vascular epithelial growth
factor-A (VEGF-A) with sub-picomolar aﬃnity, in addi-
tion to binding vascular epithelial growth factor-B
(VEGF-B) and placental growth factor (PlGF) [15].
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VELOUR trial showed statistically signiﬁcant and clini-
cally meaningful beneﬁt in median OS, PFS, and RR for
FOLFIRI plus aﬂibercept compared with FOLFIRI
alone [9]. Patients receiving FOLFIRI plus aﬂibercept
had a median OS of 13.5 months versus 12.0 months
for patients receiving FOLFIRI plus placebo, represent-
ing a relative reduction in the risk of death of 18.3% for
the aﬂibercept arm compared with the placebo arm [9].
However, this increase in median OS is likely to be an
underestimate of the clinical beneﬁt gained by the addi-
tion of aﬂibercept as the Kaplan–Meier survival curves
continue to separate past the median time point indicat-
ing that the magnitude of the treatment eﬀect of aﬂiber-
cept versus placebo is increasing over time in some
patient subgroups within VELOUR [9].
The present study reports on the OS beneﬁt and the
safety of aﬂibercept in the VELOUR trial over the time
course of the study. Analysis was based on a total of 863
deaths (placebo arm: 460; aﬂibercept arm: 403), with
median follow up time of 22.3 months overall. The
accrual period of the study was approximately
54 months followed by 11 months of follow-up after
the enrolment of the last patients. The maximum
treatment duration was 135 weeks (approximately
34 months) and the median exposure was 18.1 weeks in
the placebo arm and 21.4 weeks in the aﬂibercept arm.
2. Patients and methods
2.1. Patients
VELOUR (ClinicalTrials.gov NCT00561470) was a
large, international, randomised, placebo-controlled
phase III trial comparing the eﬃcacy and safety of
FOLFIRI plus aﬂibercept and FOLFIRI plus placebo
in patients with mCRC who had received prior treat-
ment with oxaliplatin as published previously [9].
2.2. Methodology of the VELOUR eﬃcacy and safety
analyses
For the purposes of the current analyses of the time
course of eﬃcacy and safety, only relevant elements of
the overall methodology are described. Response was
assessed according to Response Evaluation Criteria in
Solid Tumors (RECIST), version 1.0.
To characterise the time course of the safety proﬁle of
aﬂibercept-containing therapy, patients were stratiﬁed
by grade of adverse event (AE) and by treatment arm
[9]. AEs were coded using The Medical Dictionary for
Regulatory Activities (MedDRA) version 13.1 and
graded according to National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI-CTCAE)
version 3.0.Fig. 1. CONSORT chart.
Full details of the statistical tests used in these analy-
ses are described in the supplementary material (methods
section).
3. Results
The analysis of the time course of the eﬃcacy and
safety results are based on data from the VELOUR
intention-to-treat (ITT) patient population. The ITT
population comprised the 1226 patients who were ran-
domised to receive FOLFIRI plus aﬂibercept (n = 612)
or FOLFIRI plus placebo (n = 614) (Fig. 1). As previ-
ously described, the two treatment arms were well
balanced with regard to patient characteristics, disease
stage, and prior therapy [9].
3.1. Eﬃcacy
In VELOUR, an increase in median OS of
1.4 months at 12 months was observed for FOLFIRI
plus aﬂibercept when compared with FOLFIRI plus
placebo [9].
In the current analysis, the median OS improved pro-
gressively to 2.6 months at 18 months and 4.4 months at
24 months (Fig. 2). The hazard ratio (HR) for treatment
eﬀect increased from 0.860 for patients surviving up to
6 months to 0.676 for patients surviving more than
18 months (Table 1). There was minimal or no overlap
between the conﬁdence intervals by treatment arm for
the estimated probability of survival at time points
beyond 18 months, 24 months or 30 months. The
estimated probabilities of survival were 38.5% (95.34%
conﬁdence interval (CI): 34.3–42.7) compared with
30.9% (95.34% CI: 26.9–34.8) at 18 months and 28.0%
(95.34% CI: 23.7–32.4) compared with 18.7% (95.34%
CI: 14.9–22.5) at 24 months for the aﬂibercept and pla-
cebo patient groups, respectively. At 30 months, 22.3%
(95.34% CI: 17.8–26.8) of patients were estimated to
be alive in the FOLFIRI plus aﬂibercept arm compared
with 12.0% (95.34% CI: 8.0–16.0) in the FOLFIRI plus
placebo arm. The absolute percent increase in the prob-
ability of survival in the aﬂibercept arm over the placebo
arm at 12, 18, 24 and 30 months is 5.8%, 7.6%, 9.3% and
10.3%, respectively. Correspondingly, the proportional
increase in the probability of survival at 12, 18, 24 and
30 months is 11.5%, 24.6%, 49.3% and 85.8% in the
aﬂibercept arm over the placebo arm (Fig. 2).
3.2. Eﬀect of post-study treatment in VELOUR
The post-study anti-cancer treatments (summarised
in supplementary Table S1) were well balanced between
the two treatment arms, indicating that the survival
results were not inﬂuenced by such treatments.
Fig. 2. Survival probability and improvement in hazard ratio (HR) over time: Kaplan–Meier estimates of overall survival with aﬂibercept plus
ﬂuorouracil, leucovorin and irinotecan (FOLFIRI) and placebo plus FOLFIRI in VELOUR. AFLI, aﬂibercept; PBO, placebo.
Table 1
The ITT population-hazard ratios by 6-month intervals for overall
survival.*
Time (months) Hazard ratio (95.34% CI)
versus Placebo/FOLFIRI
t 6 6 0.860 (0.664–1.114)
6 < t 6 12 0.838 (0.673–1.043)
12 < t 6 18 0.782 (0.582–1.050)
t > 18 0.676 (0.463–0.988)
* Piecewise Cox proportional hazard model.
CI, conﬁdence interval; FOLFIRI, ﬂuorouracil, leucovorin and
irinotecan; ITT, intention-to-treat, t, time.
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3.3. Safety
At least one treatment-emergent AE (TEAE) was
reported for 99.2% of patients in the FOLFIRI plus
aﬂibercept arm and for 97.9% of patients in the FOLF-
IRI plus placebo arm [9]. Grade 3–4 AEs were reported
in 83.5% of patients in the FOLFIRI plus aﬂibercept
arm and 62.5% of patients in the FOLFIRI plus placebo
arm [9]. The AEs were consistent with those typically
associated with anti-VEGF treatment and the FOLFIRI
regimen. Many common AEs, including diarrhoea, sto-
matitis, infection, and hypertension, were of single
Table 2
Occurrence of selected anti-VEGF-related and chemotherapy-related grade 3–4 AEs over the course of the VELOUR trial.*
% (for 15 cycles) Anti-VEGF-associated toxicities Chemotherapy-associated toxicities
Cycle of ﬁrst occurrence of AE grade 3/4
Proteinuria Hypertension Haemorrhage Diarrhoea Stomatitis Infection Neutropenia
PBO AFLIB PBO AFLIB PBO AFLIB PBO AFLIB PBO AFLIB PBO AFLIB PBO AFLIB
Cycle 1 0.0 4.2 11.1 23.7 20.0 0.0 27.7 28.0 20.0 14.3 4.8 16.0 17.6 17.1
Cycle 2 0.0 29.2 0.0 30.5 10.0 16.7 23.4 9.3 16.7 14.3 23.8 13.3 23.5 20.0
Cycle 3 0.0 12.5 11.1 11.9 10.0 22.2 12.8 11.0 10.0 14.3 16.7 14.7 29.4 14.3
Cycle 4 14.3 8.3 11.1 5.9 0.0 11.1 4.4 11.9 3.3 9.5 4.8 4.0 11.8 11.4
Cycle 5 14.3 8.3 22.2 5.1 10.0 11.1 6.4 7.6 20.0 9.5 9.5 9.3 5.9 5.7
Cycle 6 14.3 6.3 0.0 8.5 10.0 5.6 2.1 3.4 6.7 6.0 4.8 5.3 0.0 2.9
Cycle 7 0.0 2.1 0.0 3.4 10.0 0.0 2.1 3.4 0.0 7.1 4.8 4.0 0.0 5.7
Cycle 8 0.0 2.1 0.0 0.8 10.0 16.7 2.1 2.5 0.0 2.4 2.4 5.3 0.0 2.9
Cycle 9 0.0 4.2 11.1 0.8 0.0 0.0 6.4 0.0 6.7 2.4 7.1 4.0 0.0 5.7
Cycle 10 0.0 0.0 0.0 1.7 0.0 5.6 0.0 3.4 0.0 2.4 2.4 4.0 0.0 0.0
Cycle 11 14.3 2.1 0.0 0.0 0.0 0.0 4.3 4.2 3.3 2.4 0.0 5.3 0.0 5.7
Cycle 12 14.3 2.1 0.0 2.5 10.0 0.0 0.0 3.4 3.3 3.6 0.0 1.3 5.9 0.0
Cycle 13 14.3 2.1 0.0 0.8 0.0 5.6 0.0 2.5 0.0 4.8 0.0 1.3 0.0 0.0
Cycle 14 0.0 6.3 0.0 0.0 0.0 0.0 0.0 2.5 3.3 0.0 2.4 1.3 0.0 2.9
Cycle 15 0.0 0.0 11.1 0.0 0.0 5.6 0.0 2.5 3.3 1.2 0.0 1.3 0.0 2.9
% Patients with at least 1 AE
All grade 40.7 62.2 10.7 41.4 19.0 37.8 56.5 69.2 34.9 54.8 32.7 46.2 3.0 6.5
Grade 3–4 1.2 7.9 1.5 19.3 1.7 2.9 7.8 19.3 5.0 13.7 6.9 12.3 2.8 5.7
% Patients with single occurrence of AE
Grade 3–4 100.0 85.4 88.9 74.6 100.0 83.3 93.6 76.3 96.7 86.9 88.1 92.0 100.0 86.0
% Patients recovered
All grade 12.6 28.4 92.3 88.5 90.4 91.8 95.9 92.4 97.2 93.1 90.4 90.4 94.4 95.0
Grade 3–4 28.6 64.6 100.0 91.5 100.0 88.9 97.9 92.4 96.7 96.4 88.1 86.7 94.1 94.3
AE(s), adverse event(s); PBO, placebo; AFLIB, aﬂibercept; Anti-VEGF, anti-vascular epithelial growth factor.
* Data were stratiﬁed by grade of AE.
Fig. 3. Occurrence of selected anti-vascular epithelial growth factor (VEGF)- and chemotherapy-related grade 3–4 adverse events (AEs) over the
course of VELOUR. AFLI, aﬂibercept; PBO, placebo.
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occurrence (Table 2 and Fig. 3). The majority of grade
3–4 AEs associated with aﬂibercept occurred during
the early cycles and decreased with subsequent cycles
(Fig. 3). The incidence of ﬁrst occurrence of aﬂiber-
cept-related grade 3–4 AEs peaked at cycle 1 or 2 and
decreased over later cycles (Table 2 and Fig. 4A).
Chemotherapy-associated AEs also decreased sharply
in both arms following initial event presentation (Table 2
and Fig. 4B). For instance, although aﬂibercept potenti-
ated the rate of grade 3–4 diarrhoea in cycle 1 from 2.2%
to 5.4%, in later cycles the percentage of aﬀected
patients in each arm had equalised. Overall the
A B
C D
Fig. 4. Treatment cycle of ﬁrst occurrence (A and B) and worst occurrence (C and D) of grade 3–4 events of selected anti-vascular epithelial growth
factor (VEGF)-related and chemotherapy-related adverse events (AEs).
Table 3
Number of cycles with grade 3–4 treatment-emergent AEs of speciﬁc interest: AEs with FOLFIRI plus aﬂibercept versus placebo.*
AEs Placebo/FOLFIRI 605 patients and 6127 cycles (%
cycles)
Aﬂibercept/FOLFIRI 611 patients and 6362 cycles (%
cycles)
Grade 3 Grade 4 Grade 3 Grade 4
Anti-VEGF-associated AEs
Any 125 (2.0%) 41 (0.7%) 369 (5.8%) 92 (1.4%)
Hypertension 14 (0.2%) 0 244 (3.8%) 1 (<0.1%)
Venous thromboembolic event 68 (1.1%) 40 (0.7%) 95 (1.5%) 82 (1.3%)
Haemorrhage 13 (0.2%) 0 20 (0.3%) 1 (<0.1%)
Arterial thromboembolic event 24 (0.4%) 0 8 (0.1%) 6 (<0.1%)
Acute drug reaction 5 (<0.1%) 0 3 (<0.1%) 0
Gastrointestinal perforation 1 (<0.1%) 1 (<0.1%) 1 (<0.1%) 2 (<0.1%)
Wound healing 0 0 3 (<0.1%) 0
Fistula from gastrointestinal
origin
1 (<0.1%) 0 2 (<0.1%) 0
Cardiac dysfunction 0 0 1 (<0.1%) 0
Chemotherapy-associated AEs
Diarrhoea 0.9% 0.2% 2.8% 0.3%
Stomatitis 5% 0 13.7% 0.2%
Infection 42 (6.9%) 5 (0.8%) 75 (12.3%) 8 (1.3%)
AEs, adverse events; Anti-VEGF, anti-vascular endothelial growth factor; FOLFIRI, ﬂuorouracil, leucovorin and irinotecan.
* Data were stratiﬁed by grade of AE.
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percentage of cycles associated with grade 3–4 diarrhoea
in the aﬂibercept arm was 3.1% compared with 1.1% in
the control FOLFIRI arm (Table 3). AEs were generally
reversible and the vast majority of patients recovered
from grade 3–4 events with the exception of those
patients who developed proteinuria. Proteinuria of any
grade was reported in 62% of patients receiving aﬂiber-
cept, but the majority of proteinuria events that
occurred on study were mild to moderate in nature
(grade 1–2) (Table 2). GradeP 3 proteinuria occurred
in 7.9% of the aﬂibercept-treated patients, but grade 4
proteinuria or nephrotic syndrome was recorded for 2
(0.3%) patients. Only 23.7% of the patients who experi-
enced proteinuria gradeP 1 had a single event.
Overall, 605 patients received a total of 6127 treat-
ment cycles in the placebo arm, with a median of 8
cycles per patient (1–67), and 611 patients received
6362 cycles in the aﬂibercept arm, with a median of nine
cycles per patient (1–50) (Table 3). Further safety and
premature discontinuation data are summarised in
Supplementary Table S2. Dosing data (cycle delay or
dose modiﬁcations over cycles in both arms) are summa-
rised in supplementary Table S3.
4. Discussion
Patients with mCRC who have progressed on oxalipl-
atin-based treatment have limited therapeutic options,
although phase III trials of anti-angiogenic and anti-
EGFR therapy have shown some clinical beneﬁt
[10,13]. In VELOUR, FOLFIRI plus aﬂibercept demon-
strated statistically signiﬁcant and clinically meaningful
sustained OS (primary end-point), PFS and ORR (sec-
ondary end-points) beneﬁts in these patients regardless
of any potential impact from dose reductions, patient
discontinuations, or overall toxicity. The addition of
aﬂibercept to FOLFIRI was associated with a reduction
in the risk of death of 18.3% in the FOLFIRI plus aﬂib-
ercept arm and a 24.2% reduction in the risk of disease
progression [9]. Moreover, in VELOUR, in a prior oxa-
liplatin treated population, the RR was signiﬁcantly
improved by the addition of aﬂibercept to FOLFIRI
(19.8% versus 11.1%, respectively) [9].
In the primary analysis of the VELOUR study, the
estimated median OS in the placebo arm was
12.06 months (95.34% CI: 11.07–13.11), compared with
13.50 months (95.34% CI: 12.52–14.95) in the aﬂibercept
arm [9]. However, the increase in median OS underesti-
mates the clinical beneﬁt gained for the overall patient
population as the Kaplan–Meier survival curves con-
tinue to separate past the median time point indicating
that the magnitude of the aﬂibercept treatment eﬀect is
increasing over time. This is also apparent in the OS
HR which is more reﬂective of the treatment eﬀect across
the entire population; the estimated HR of 0.817 [9]
translates into a theoretical improvement in median OS
from 12 months to 14.7 months, which is larger than
the median improvement derived from the Kaplan–
Meier graph. The assessment of the HRs over time in
the present analysis (Fig. 2) is consistent with a propor-
tional improvement in survival rate at 24 months of
50% (28.0% for aﬂibercept versus 18.7% for placebo)
and at 30 months of nearly double (22.3% for aﬂibercept
versus 12.0% for placebo), indicating that the magnitude
of the treatment eﬀect of aﬂibercept increased over time
compared with placebo. In this analysis, the survival
probabilities at additional time points, are emphasised
in order to better characterise the treatment eﬀect, in
particular at 18 and 24 months, compared with just the
median OS. Furthermore, the eﬃcacy time course
demonstrates how the treatment eﬀect is maintained
and varies over time. However, it is important to note
that the study is not powered to demonstrate a signiﬁcant
diﬀerence in OS at each single time point as the number
of patients still alive has decreased.
Tumour angiogenesis relies primarily on VEGF-A-
driven responses, but other angiogenic growth factors
including VEGF-B and PIGF work complementarily
to regulate tumour growth and are also associated with
resistance to anti-angiogenic therapy in mCRC. Aﬂiber-
cept’s high aﬃnity for PlGF and its ability to bind more
ligands in the tumour microenvironment, oﬀers more
potent anti-angiogenic activity with the potential for
better tumour response, disease control and possibly
improved PFS and OS times [9,16,17]. However, this
remains to be tested in the clinical setting.
In general, AEs associated with the FOLFIRI plus
aﬂibercept regimen were due to either anti-VEGF class
eﬀects or enhancement of chemotherapy-related toxici-
ties. Notably, however, not only did the VELOUR
study design restrict the use of prophylactic granulocyte
colony-stimulating factor but there was a per-protocol
requirement for the initial use of full-dose FOLFIRI
in both arms.
The majority of grade 3–4 AEs occurred during early
treatment cycles and in a very small proportion of the
total cycles administered. One can speculate that this
may be due in part to the possibility that once a patient
experienced an AE, it was adequately managed and trea-
ted in subsequent cycles. Indeed, the pattern of cycle
delays and/or dose modiﬁcations appears similar to
the pattern of the time course of AEs, with the majority
of dose delays and modiﬁcations occurring in the early
cycles. Where patients experienced a grade 3–4 event,
they were generally single episodes and the majority of
patients recovered from these events. Importantly, both
gradeP 3 proteinuria and hypertension were mostly of
single occurrence and the majority were reversible. The
AE proﬁle did not aﬀect patients’ abilities to continue
to receive treatment.
It is also worth noting that in VELOUR, the rate of
proteinuria in the placebo arm was higher than
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expected, i.e. 40.7% with any grade and 1% with grade
3–4. For the aﬂibercept arm, any grade of hypertension
was reported in 41% of patients compared with 20% of
patients with grade 3–4 hypertension. A potential reason
may be the enhanced aﬃnity of aﬂibercept for VEGF-A
and stronger inhibition of the VEGF pathway. In
VELOUR, the adverse vascular eﬀects seen were not
unexpected, and were usually attributable directly or
indirectly to the general class of anti-VEGF eﬀects also
seen with other anti-angiogenic medications.
Although cross-trial comparisons need to be inter-
preted with caution, the limited published data available
for the combination of bevacizumab and irinotecan-
based chemotherapy also report an enhancement of
grade 3–4 chemotherapy-related toxicities such as leuco-
paenia and diarrhoea, or VEGF inhibitor class eﬀects
such as hypertension, thrombotic events or proteinuria
[4]. Other large phase III and IV trials of similar regi-
mens have reported rates of grade 3 or 4 hypertension
and diarrhoea of greater than 10% [4,10,18,19].
Increased toxicity is not unexpected when biologics
are added to combination therapy [4,10,13,18,20–23].
Indeed, the addition of cetuximab to irinotecan in sec-
ond line enhanced chemotherapy-related toxicities in
terms of diarrhoea (28.4% versus 15.7%), fatigue (7.7%
versus 3.3%) or neutropenia (31.8% versus 25.4%) [12].
The incidence of fatal AEs reported with aﬂibercept
plus FOLFIRI (2.3%) was comparable or less than those
reported for other regimens used in the second-line man-
agement of mCRC [24]. The incidence of fatal AEs with
bevacizumab plus FOLFOX4 was 4.9% [25] and with
cetuximab plus irinotecan was 3.2% [26]. In VELOUR,
TEAEs leading to death occurred in 1.0% of patients
in the aﬂibercept arm and 0.5% of those in the placebo
arm (Sanoﬁ data on ﬁle) and were comparable with
those reported for other studies [10,12].
In conclusion, the present survival analysis of
VELOUR over diﬀerent time points up to 30 months
demonstrates an increase in survival probability over
time for patients treated with FOLFIRI plus aﬂibercept
and a persistence of the survival beneﬁt beyond the med-
ian survival time of 13.5 months. This clinical beneﬁt was
however accompanied by an expected increase in the
AEs associated with both the chemotherapy backbone
and aﬂibercept. The time course analysis of AEs in
VELOUR provides health care practitioners with the
ability to anticipate expected treatment toxicities and
manage them accordingly. The anticipation and appro-
priate management of AEs is all the more important in
light of an on-treatment PFS analysis of VELOUR
which supports the continuation of aﬂibercept treatment
as close to progression as is reasonably possible [27]. This
on-treatment PFS analysis, within 28 days of end of
treatment, demonstrated a signiﬁcantly improved treat-
ment eﬀect for the addition of aﬂibercept to FOLFIRI
in mCRC (HR = 0.55 [95% CI: 0.46–0.66] P < 0.00001)
over the primary VELOUR analysis (HR = 0.76 [95%
CI: 0.66–0.87] P = 0.00007) [27].
This integrated analysis of the time course of both the
eﬃcacy and safety of the aﬂibercept plus FOLFIRI reg-
imen, complements and expands the original results of
the VELOUR study making this regimen an eﬀective
and manageable therapeutic option for patients with
mCRC previously treated with an oxaliplatin regimen
and demonstrates a meaningful clinical beneﬁt, which
is sustained over a signiﬁcant time period.
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